BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 21045835)

  • 1. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
    Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
    Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
    Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
    J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
    Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
    BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
    Arora S; Bhardwaj A; Singh S; Srivastava SK; McClellan S; Nirodi CS; Piazza GA; Grizzle WE; Owen LB; Singh AP
    J Biol Chem; 2013 Jul; 288(29):21197-21207. PubMed ID: 23740244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.
    Zhang H; Wu H; Guan J; Wang L; Ren X; Shi X; Liang Z; Liu T
    Oncotarget; 2015 Feb; 6(5):3085-97. PubMed ID: 25609203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.
    Singh AP; Arora S; Bhardwaj A; Srivastava SK; Kadakia MP; Wang B; Grizzle WE; Owen LB; Singh S
    J Biol Chem; 2012 Nov; 287(46):39115-24. PubMed ID: 22995914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
    Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
    Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
    Yu C; Chen S; Guo Y; Sun C
    Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
    [No Abstract]   [Full Text] [Related]  

  • 13. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
    Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
    Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
    Xing L; Lv HT; Liu SG; Wang WB; Zhang TF; Liu JH; Bian W
    Scand J Gastroenterol; 2021 Aug; 56(8):914-919. PubMed ID: 34165373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
    Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
    J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.
    Ping YF; Yao XH; Jiang JY; Zhao LT; Yu SC; Jiang T; Lin MC; Chen JH; Wang B; Zhang R; Cui YH; Qian C; Wang Jm; Bian XW
    J Pathol; 2011 Jul; 224(3):344-54. PubMed ID: 21618540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
    Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
    Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways.
    Shen X; Artinyan A; Jackson D; Thomas RM; Lowy AM; Kim J
    Pancreas; 2010 Jan; 39(1):81-7. PubMed ID: 19820417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
    Brandi G; Tavolari S; Guarnieri T; Di Marco M; Paterini P; Macchini M; Di Girolamo S; Papi A; De Rosa F; Biasco G
    Pancreas; 2014 Jan; 43(1):53-63. PubMed ID: 24201777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.